Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Special Deliveries: Navigating The Growing Complexities Of Pharmaceutical Cold Chains
Pharmaceutical cold chain products are growing in number, complexity and reach. While life sciences organizations and their partners have been steadily investing in capabilities to effectively manufacture and distribute them, scaling them at the speed of innovation in an era of increasing regulatory and environmental requirements is more and more challenging.
Looking Beyond The Deal In England
Agreement of deals that promise better value for money and enhanced patient access to new treatments has become routine in England, but are they delivering?
The E in ESG: Beware Green Claims That Might Backfire
Health care companies making carbon neutrality claims must tread a careful line while ensuring full accountability. CMS Vienna partner Gabriela Staber points to some of the risks businesses should be aware of when making sustainability claims.
How To Master The New Legal Responsibilities Introduced By The CTR
The Clinical Trials Regulation finally entered into application on 31 January 2022, replacing the largely national, and sometimes inconsistent, rules created by the Clinical Trials Directive. In this article, law firm Cooley advises on the changes introduced by the CTR and explores ways in which firms can reduce their contractual risks and potential legal liability.
The Serious Business Of Digital Medical Games
There are fewer than a handful of approved prescription video game digital therapeutics, but gamification in patient care is proving its worth as a novel way of treating a range of conditions, from vision loss to dyslexia and ADHD. Now, the onus is on lawmakers and insurers to create a clear path towards reimbursement.
Worldwide Regulators Warm Up To Medical Marijuana
Both the US and EU are gradually warming up to medical marijuana, but clunky and inadequate regulation threatens to curtail the growth of a burgeoning industry.
The Cell And Gene Therapy Sector In 2023: A Wave Is Coming – Are We Ready?
From a scientific perspective, the outlook for patient with rare disease has never been brighter. This year, 13 new cell or gene therapies could be approved in the US, Europe or both by the end of 2023. However, the challenges that stop patients accessing new therapies remain. Could this year be the turning point when our health care systems start to catch up with our science?
Dark Territory: Lifting The Veil On GPOs And PBMs
Based on a new report by the Wharton School, this article tackles criticisms against the intermediaries that connect buyers and sellers, the GPO and PBM. It also analyzes the existential threats facing these intermediaries such as 'safe harbors', threats of disintermediation, and the consolidation of suppliers.
The E In ESG: An Opportunity For The Medtech Industry
Can environmental sustainability become a business differentiator? Some companies are already onto it. Boston Consulting Group puts the case in favor of the argument.
Outlook 2023: The Irresistible Forces Shaping Medtech Markets And Industry
The integration of smart connected care, broadening of diagnosis and therapy into new settings and improvement of chronic disease outcomes will continue to shape the market for devices and diagnostics companies for years to come. But there is also a maze of short-term macroeconomic issues for medtechs to work through.
2023: Will The Road Ahead Be Any Smoother For The EU’s Medtech Regulations?
Originally intended to increase medical device safety, the implementation of the EU’s medtech regulation was so hampered in 2022 that it had started to look as if the new regulations were a bigger potential threat to patients than any of the scandals leading to its more stringent requirements. With the European Commission’s latest plans to ease challenges around implementation, will 2023 be a more positive year for the EU medtech sector?
Flight Of The Navigator: Bluebird bio's Andrew Obenshain
For 12 years, bluebird bio has been developing gene therapies for rare genetic disease and now, with two approvals under its belt, the company is continuing to explore uncharted territory as it brings forward innovative new treatments. Holding the map is CEO Andrew Obenshain.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.